Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells

Cancer Genetics and Cytogenetics

Volumn 175, Issue 2, 2007, Pages 107-116

  Ren, Yun ^a   Liu, Xishi ^a   Ma, Duan ^a   Feng, Youji ^a   Zhong, Nanbert ^b,c  

^a FUDAN UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROGESTERONE; PROGESTERONE RECEPTOR; RNA; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENDOMETRIUM CANCER; EXON; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SEQUENCE; GROWTH INHIBITION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RECEPTORS, PROGESTERONE;

EID: 34249808191     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.02.002     Document Type: Article

References (39)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Syed V., and Ho S.M. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22 (2003) 6883-6890
3. Amant F., Cadron I., Fuso L., Berteloot P., de Jonge E., Jacomen G., Van Robaeys J., Neven P., Moerman P., and Vergote I. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 98 (2005) 274-280
4. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., and Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9 (1990) 1603-1614
5. Hanekamp E.E., Gielen S.C., Smid-Koopman E., Kuhne L.C., de Ruiter P.E., Chadha-Ajwani S., Brinkmann A.O., Grootegoed J.A., Burger C.W., Huikeshoven F.J., and Blok L.J. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9 (2003) 4190-4199
6. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., and Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 69 (1998) 220-225
7. Nyholm H.C., Christensen I.J., and Nielsen A.L. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 59 (1995) 347-351
8. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 321 (1986) 209-213
9. Antequera F., Boyes J., and Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62 (1990) 503-514
10. Sasaki M., Dharia A., Oh B.R., Tanaka Y., Fujimoto S., and Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res 61 (2001) 97-102
11. Xiong Y., Dowdy S.C., Gonzalez Bosquet J., Zhao Y., Eberhardt N.L., Podratz K.C., and Jiang S.W. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 99 (2005) 135-141
12. Santi D.V., Norment A., and Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81 (1984) 6993-6997
13. Xiong Y., Dowdy S.C., Podratz K.C., Jin F., Attewell J.R., Eberhardt N.L., and Jiang S.W. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 65 (2005) 2684-2689
14. Gardiner-Garden M., and Frommer M. CpG islands in vertebrate genomes. J Mol Biol 196 (1987) 261-282
15. Liu Y., Peterson D.A., Kimura H., and Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69 (1997) 581-593
16. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 (1991) 271-279
17. Dai D., Kumar N.S., Wolf D.M., and Leslie K.K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol 184 (2001) 790-797
18. Ehrlich C.E., Young P.C., Stehman F.B., Sutton G.P., and Alford W.M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158 (1988) 796-807
19. Tazi J., and Bird A. Alternative chromatin structure at CpG islands. Cell 60 (1990) 909-920
20. Nguyen C., Liang G., Nguyen T.T., Tsao-Wei D., Groshen S., Lubbert M., Zhou J.H., Benedict W.F., and Jones P.A. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 93 (2001) 1465-1472
21. Ferguson A.T., Lapidus R.G., and Davidson N.E. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene 17 (1998) 577-583
22. Buschhausen G., Wittig B., Graessmann M., and Graessmann A. Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 84 (1987) 1177-1181
23. Rideout III W.M., Eversole-Cire P., Spruck III C.H., Hustad C.M., Coetzee G.A., Gonzales F.A., and Jones P.A. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol 14 (1994) 6143-6152
24. Hsieh C.L. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 14 (1994) 5487-5494
25. Hsieh C.L. Stability of patch methylation and its impact in regions of transcriptional initiation and elongation. Mol Cell Biol 17 (1997) 5897-5904
26. Kass S.U., Goddard J.P., and Adams R.L. Inactive chromatin spreads from a focus of methylation. Mol Cell Biol 13 (1993) 7372-7379
27. Liu Z.J., and Maekawa M. Polymerase chain reaction-based methods of DNA methylation analysis. Anal Biochem 317 (2003) 259-265
28. Hug M., Silke J., Georgiev O., Rusconi S., Schaffner W., and Matsuo K. Transcriptional repression by methylation: cooperativity between a CpG cluster in the promoter and remote CpG-rich regions. FEBS Lett 379 (1996) 251-254
29. Bestor T., Laudano A., Mattaliano R., and Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203 (1988) 971-983
30. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
31. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
32. Reik W., Kelsey G., and Walter J. Dissecting de novo methylation. Nat Genet 23 (1999) 380-382
33. Bestor T.H. The DNA methyltransferases of mammals. Hum Mol Genet 9 (2000) 2395-2402
34. Christman J.K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21 (2002) 5483-5495
35. Li H., Rauch T., Chen Z.X., Szabo P.E., Riggs A.D., and Pfeifer G.P. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J Biol Chem 281 (2006) 19489-19500
36. Schneider-Stock R., Diab-Assef M., Rohrbeck A., Foltzer-Jourdainne C., Boltze C., Hartig R., Schonfeld P., Roessner A., and Gali-Muhtasib H. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther 312 (2005) 525-536
37. Arnett-Mansfield R.L., deFazio A., Wain G.V., Jaworski R.C., Byth K., Mote P.A., and Clarke C.L. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61 (2001) 4576-4582
38. Hsi L.C., Xi X., Wu Y., and Lippman S.M. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol Cancer Ther 4 (2005) 1740-1746
39. Choi Y.H. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 27 (2005) 473-479